摘要:
The present invention provides an enteric coated composition for oral administration of a chloride channel opener which can provide improved pharmaceutical activity with reduced adverse side effect such as nausea.
摘要:
An antagonist against endothelin believed to relate to the causes of diseases such as hypertension, Buerger's disease, asthma, eyeground diseases, and the like. The antagonist comprises a 15-ketoprostaglandin E compound, especially, a 13,14-dihydro15-keto-16-mono- or dihalogenoprostaglandin.
摘要:
An object of the present invention is to provide an anti-constipation composition containing a halogenated-bi-cyclic compound as an active ingredient in a ratio of bi-cyclic/mono-cyclic structure of at least 1 : 1. The halogenated-bi-cyclic compound is represented by Formula (I): where X1 and X2 are preferably both fluorine atoms. The composition can be used to treat constipation without substantive side-effects, such as stomachache.
摘要:
Disclosed is a composition for treatment of external secretion disorders comprising, as an active ingredient a fatty acid derivative. The composition of the present invention is useful for treatment of at least one condition selected from hypolacrimation including disorder of basal tear secretion, dry-eye syndrome, hyposalivation and dry-mouth syndrome.
摘要:
A dosage unit for treating constipation in a human patient is described. The dosage unit of the invention comprises a halogenated prostaglandin analog and a pharmaceutically suitable excipient. The dosage unit relieves constipation without substantial side effects.
摘要:
Disclosed is a novel use of a prostaglandin compound as a chloride channel opener. According to the instant invention, chloride channels in a mammalian subject can be opened by a prostaglandin compound to facilitate chloride ion transportation.
摘要:
Provided is a composition for treatment of drug-induced constipation comprising a 15-keto-prostaglandin compound as an active ingredient. The composition of the present invention has a strong antagonistic action against drug-induced constipation without substantially losing the main effect of the drug.
摘要:
Disclosed is a new use of 15-keto-prostaglandin compound as an apoptosis inhibitor. Said compound can inhibit apoptosis effectively and is useful for treatment of a subject such as a human having a disease or condition associated with apoptosis.